WO2002055489A2 - Techniques liees a la kinase pim - Google Patents

Techniques liees a la kinase pim Download PDF

Info

Publication number
WO2002055489A2
WO2002055489A2 PCT/US2001/050535 US0150535W WO02055489A2 WO 2002055489 A2 WO2002055489 A2 WO 2002055489A2 US 0150535 W US0150535 W US 0150535W WO 02055489 A2 WO02055489 A2 WO 02055489A2
Authority
WO
WIPO (PCT)
Prior art keywords
socs
pim
agent
protein
phosphorylation
Prior art date
Application number
PCT/US2001/050535
Other languages
English (en)
Other versions
WO2002055489A3 (fr
Inventor
Paul Rothman
Peter Chen
Original Assignee
Univ Columbia
Paul Rothman
Peter Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Paul Rothman, Peter Chen filed Critical Univ Columbia
Priority to AU2002246864A priority Critical patent/AU2002246864A1/en
Priority to US10/250,380 priority patent/US20040109868A1/en
Publication of WO2002055489A2 publication Critical patent/WO2002055489A2/fr
Publication of WO2002055489A3 publication Critical patent/WO2002055489A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des techniques permettant de traiter une réaction allergique, l'asthme et la survenue d'un rejet de greffe chez un patient. Ces techniques consistent à administrer à ce patient un agent qui augmente la quantité et/ou l'activité d'une kinase Pim. Cette invention concerne aussi une technique permettant de déterminer si un agent augmente la phosphorylation d'une protéine Socs-1 par une kinase Pim.
PCT/US2001/050535 2000-12-27 2001-12-27 Techniques liees a la kinase pim WO2002055489A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002246864A AU2002246864A1 (en) 2000-12-27 2001-12-27 Pim kinase-related methods
US10/250,380 US20040109868A1 (en) 2001-12-27 2001-12-27 Pim kinase-related methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25842100P 2000-12-27 2000-12-27
US60/258,421 2000-12-27

Publications (2)

Publication Number Publication Date
WO2002055489A2 true WO2002055489A2 (fr) 2002-07-18
WO2002055489A3 WO2002055489A3 (fr) 2002-10-03

Family

ID=22980473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050535 WO2002055489A2 (fr) 2000-12-27 2001-12-27 Techniques liees a la kinase pim

Country Status (2)

Country Link
AU (1) AU2002246864A1 (fr)
WO (1) WO2002055489A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111001A1 (fr) * 2003-06-13 2004-12-23 Actelion Pharmaceuticals Ltd 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine comme inhibiteur de la glucosylceramide synthase (gcs)
US8071780B2 (en) 2003-06-13 2011-12-06 Actelion Pharmaceuticals Ltd. 2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
US9200004B2 (en) 2013-01-15 2015-12-01 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9862705B2 (en) 2015-09-09 2018-01-09 Incyte Corporation Salts of a pim kinase inhibitor
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022219B2 (en) 2003-06-13 2011-09-20 Actelion Pharmaceuticals Ltd. 2-hydroxymethy1-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine as glucosylceramide synthase (Gcs) inhibitor
US8071780B2 (en) 2003-06-13 2011-12-06 Actelion Pharmaceuticals Ltd. 2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
WO2004111001A1 (fr) * 2003-06-13 2004-12-23 Actelion Pharmaceuticals Ltd 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine comme inhibiteur de la glucosylceramide synthase (gcs)
US9676750B2 (en) 2013-01-14 2017-06-13 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9200004B2 (en) 2013-01-15 2015-12-01 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
US9550765B2 (en) 2013-01-15 2017-01-24 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
US10828290B2 (en) 2013-01-15 2020-11-10 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
US11229631B2 (en) 2013-01-15 2022-01-25 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
US10517858B2 (en) 2013-01-15 2019-12-31 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors
US10265307B2 (en) 2013-01-15 2019-04-23 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
US9849120B2 (en) 2013-01-15 2017-12-26 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US10000507B2 (en) 2013-08-23 2018-06-19 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9890162B2 (en) 2014-07-14 2018-02-13 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9802918B2 (en) 2015-05-29 2017-10-31 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US11066387B2 (en) 2015-09-09 2021-07-20 Incyte Corporation Salts of a Pim kinase inhibitor
US10336728B2 (en) 2015-09-09 2019-07-02 Incyte Corporation Salts of a Pim kinase inhibitor
US9862705B2 (en) 2015-09-09 2018-01-09 Incyte Corporation Salts of a pim kinase inhibitor
US11505540B2 (en) 2015-09-09 2022-11-22 Incyte Corporation Salts of a Pim kinase inhibitor
US10450296B2 (en) 2015-10-02 2019-10-22 Incyte Corporation Heterocyclic compounds useful as Pim kinase inhibitors
US11053215B2 (en) 2015-10-02 2021-07-06 Incyte Corporation Heterocyclic compounds useful as Pim kinase inhibitors
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms

Also Published As

Publication number Publication date
AU2002246864A1 (en) 2002-07-24
WO2002055489A3 (fr) 2002-10-03

Similar Documents

Publication Publication Date Title
Xing et al. The protein kinase KSR interacts with 14-3-3 protein and Raf
Chen et al. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA
Campbell et al. Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants.
Bollag et al. Differential regulation of rasGAP and neurofibromatosis gene product activities
Hart et al. IQGAP1, a calmodulin‐binding protein with a rasGAP‐related domain, is a potential effector for cdc42Hs.
Chang et al. The interaction of Src and RACK1 is enhanced by activation of protein kinase C and tyrosine phosphorylation of RACK1
Pathan et al. Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1
Agostini et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder
US5582995A (en) Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US20010026796A1 (en) TCL1 enhances Akt kinase activity and mediates its nuclear translocation
US6962792B1 (en) Methods and means for inhibition of Cdk4 activity
WO2002055489A2 (fr) Techniques liees a la kinase pim
EP0859839A1 (fr) ACTIVATION DE LA PROTEINE p53
JP3421217B2 (ja) Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
US6103692A (en) Inhibiting protein interactions
US6416759B1 (en) Antiproliferative Sgk reagents and methods
US6528270B1 (en) Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
US20040109868A1 (en) Pim kinase-related methods
US7364870B2 (en) MK2 interacting proteins
EP0889971A1 (fr) Modulateur de la phosphatase
US6498139B1 (en) Remedies for diseases caused by insulin resistance
US6987089B1 (en) Mouse CIA protein and CIA gene having anti-apoptotic activity as a selective inhibitor of CAD interacting ASK1 use thereof
Yoo et al. Interaction of the p23/p198 protein with ErbB-3
Solt The interaction with NEMO regulates the function of IKKα
Horn The role of p21Cip1/Waf1 and CDK2/cyclin E in regulating centrosome duplication

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10250380

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP